Novel Drug Delivery Systems Industry Research Report 2024
Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms.
Advantages of Novel Drug Delivery System are: Optimum dose at the right time and right location, efficient use of expensive drugs, excipients and reduction in production cost, Beneficial to patients, better therapy, improved comfort and standard of living.
According to APO Research, The global Novel Drug Delivery Systems market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
Global Novel Drug Delivery Systems key players include Amgen, Teva, Roche, UCB (Union Chimique Belge), etc. Global top four manufacturers hold a share over 40%.
North America is the largest market, with a share about 50%, followed by Asia-Pacific and Europe, both have a share over 40 percent.
In terms of product, PEGylated Proteins & Polypeptides is the largest segment, with a share about 40%. And in terms of application, the largest application is Hospitals & Clinic, followed by Cancer Treatment Centers, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Novel Drug Delivery Systems, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Drug Delivery Systems.
The Novel Drug Delivery Systems market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Novel Drug Delivery Systems market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Novel Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Novel Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Novel Drug Delivery Systems.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Novel Drug Delivery Systems companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Chapter 13: The main points and conclusions of the report.
Advantages of Novel Drug Delivery System are: Optimum dose at the right time and right location, efficient use of expensive drugs, excipients and reduction in production cost, Beneficial to patients, better therapy, improved comfort and standard of living.
According to APO Research, The global Novel Drug Delivery Systems market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
Global Novel Drug Delivery Systems key players include Amgen, Teva, Roche, UCB (Union Chimique Belge), etc. Global top four manufacturers hold a share over 40%.
North America is the largest market, with a share about 50%, followed by Asia-Pacific and Europe, both have a share over 40 percent.
In terms of product, PEGylated Proteins & Polypeptides is the largest segment, with a share about 40%. And in terms of application, the largest application is Hospitals & Clinic, followed by Cancer Treatment Centers, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Novel Drug Delivery Systems, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Drug Delivery Systems.
The Novel Drug Delivery Systems market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Novel Drug Delivery Systems market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Amgen
- Teva
- Roche
- UCB (Union Chimique Belge)
- Celgene
- Merck
- Gilead Sciences
- Sanofi
- Pfizer
- Takeda
- Bausch&Lomb
- Samyang Biopharmaceuticals
- Johnson & Johnson
- TOLMAR
- Astellas
- AMAG Pharmaceuticals
- AbbVie
- Dr Reddy
- AstraZeneca
- Aspen
- Acrotech Biopharma
- TWi Pharmaceuticals
- Liposomes
- PEGylated Proteins & Polypeptides
- Polymer Nanoparticle
- Protein–drug Conjugates
- Others
- Hospitals & Clinic
- Cancer Treatment Centers
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Novel Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Novel Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Novel Drug Delivery Systems.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Novel Drug Delivery Systems companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Chapter 13: The main points and conclusions of the report.
1 PREFACE
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Novel Drug Delivery Systems by Type
2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
2.2.2 Liposomes
2.2.3 PEGylated Proteins & Polypeptides
2.2.4 Polymer Nanoparticle
2.2.5 Protein–drug Conjugates
2.2.6 Others
2.3 Novel Drug Delivery Systems by Application
2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
2.3.2 Hospitals & Clinic
2.3.3 Cancer Treatment Centers
2.3.4 Others
2.4 Assumptions and Limitations
3 NOVEL DRUG DELIVERY SYSTEMS BREAKDOWN DATA BY TYPE
3.1 Global Novel Drug Delivery Systems Historic Market Size by Type (2019-2024)
3.2 Global Novel Drug Delivery Systems Forecasted Market Size by Type (2025-2030)
4 NOVEL DRUG DELIVERY SYSTEMS BREAKDOWN DATA BY APPLICATION
4.1 Global Novel Drug Delivery Systems Historic Market Size by Application (2019-2024)
4.2 Global Novel Drug Delivery Systems Forecasted Market Size by Application (2019-2024)
5 GLOBAL GROWTH TRENDS
5.1 Global Novel Drug Delivery Systems Market Perspective (2019-2030)
5.2 Global Novel Drug Delivery Systems Growth Trends by Region
5.2.1 Global Novel Drug Delivery Systems Market Size by Region: 2019 VS 2023 VS 2030
5.2.2 Novel Drug Delivery Systems Historic Market Size by Region (2019-2024)
5.2.3 Novel Drug Delivery Systems Forecasted Market Size by Region (2025-2030)
5.3 Novel Drug Delivery Systems Market Dynamics
5.3.1 Novel Drug Delivery Systems Industry Trends
5.3.2 Novel Drug Delivery Systems Market Drivers
5.3.3 Novel Drug Delivery Systems Market Challenges
5.3.4 Novel Drug Delivery Systems Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Novel Drug Delivery Systems Players by Revenue
6.1.1 Global Top Novel Drug Delivery Systems Players by Revenue (2019-2024)
6.1.2 Global Novel Drug Delivery Systems Revenue Market Share by Players (2019-2024)
6.2 Global Novel Drug Delivery Systems Industry Players Ranking, 2022 VS 2023 VS 2024
6.3 Global Key Players of Novel Drug Delivery Systems Head office and Area Served
6.4 Global Novel Drug Delivery Systems Players, Product Type & Application
6.5 Global Novel Drug Delivery Systems Players, Date of Enter into This Industry
6.6 Global Novel Drug Delivery Systems Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Novel Drug Delivery Systems Market Size (2019-2030)
7.2 North America Novel Drug Delivery Systems Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 North America Novel Drug Delivery Systems Market Size by Country (2019-2024)
7.4 North America Novel Drug Delivery Systems Market Size by Country (2025-2030)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Novel Drug Delivery Systems Market Size (2019-2030)
8.2 Europe Novel Drug Delivery Systems Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Europe Novel Drug Delivery Systems Market Size by Country (2019-2024)
8.4 Europe Novel Drug Delivery Systems Market Size by Country (2025-2030)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Russia
8.10 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Novel Drug Delivery Systems Market Size (2019-2030)
9.2 Asia-Pacific Novel Drug Delivery Systems Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Asia-Pacific Novel Drug Delivery Systems Market Size by Country (2019-2024)
9.4 Asia-Pacific Novel Drug Delivery Systems Market Size by Country (2025-2030)
9.5 China
9.6 Japan
9.7 South Korea
9.8 Southeast Asia
9.9 India
9.10 Australia
10 LATIN AMERICA
10.1 Latin America Novel Drug Delivery Systems Market Size (2019-2030)
10.2 Latin America Novel Drug Delivery Systems Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Latin America Novel Drug Delivery Systems Market Size by Country (2019-2024)
10.4 Latin America Novel Drug Delivery Systems Market Size by Country (2025-2030)
10.5 Mexico
10.6 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Novel Drug Delivery Systems Market Size (2019-2030)
11.2 Middle East & Africa Novel Drug Delivery Systems Market Growth Rate by Country: 2019 VS 2023 VS 2030
11.3 Middle East & Africa Novel Drug Delivery Systems Market Size by Country (2019-2024)
11.4 Middle East & Africa Novel Drug Delivery Systems Market Size by Country (2025-2030)
11.5 Turkey
11.6 Saudi Arabia
11.7 UAE
12 PLAYERS PROFILED
12.1 Amgen
12.1.1 Amgen Company Information
12.1.2 Amgen Business Overview
12.1.3 Amgen Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.1.4 Amgen Novel Drug Delivery Systems Product Portfolio
12.1.5 Amgen Recent Developments
12.2 Teva
12.2.1 Teva Company Information
12.2.2 Teva Business Overview
12.2.3 Teva Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.2.4 Teva Novel Drug Delivery Systems Product Portfolio
12.2.5 Teva Recent Developments
12.3 Roche
12.3.1 Roche Company Information
12.3.2 Roche Business Overview
12.3.3 Roche Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.3.4 Roche Novel Drug Delivery Systems Product Portfolio
12.3.5 Roche Recent Developments
12.4 UCB (Union Chimique Belge)
12.4.1 UCB (Union Chimique Belge) Company Information
12.4.2 UCB (Union Chimique Belge) Business Overview
12.4.3 UCB (Union Chimique Belge) Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.4.4 UCB (Union Chimique Belge) Novel Drug Delivery Systems Product Portfolio
12.4.5 UCB (Union Chimique Belge) Recent Developments
12.5 Celgene
12.5.1 Celgene Company Information
12.5.2 Celgene Business Overview
12.5.3 Celgene Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.5.4 Celgene Novel Drug Delivery Systems Product Portfolio
12.5.5 Celgene Recent Developments
12.6 Merck
12.6.1 Merck Company Information
12.6.2 Merck Business Overview
12.6.3 Merck Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.6.4 Merck Novel Drug Delivery Systems Product Portfolio
12.6.5 Merck Recent Developments
12.7 Gilead Sciences
12.7.1 Gilead Sciences Company Information
12.7.2 Gilead Sciences Business Overview
12.7.3 Gilead Sciences Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.7.4 Gilead Sciences Novel Drug Delivery Systems Product Portfolio
12.7.5 Gilead Sciences Recent Developments
12.8 Sanofi
12.8.1 Sanofi Company Information
12.8.2 Sanofi Business Overview
12.8.3 Sanofi Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.8.4 Sanofi Novel Drug Delivery Systems Product Portfolio
12.8.5 Sanofi Recent Developments
12.9 Pfizer
12.9.1 Pfizer Company Information
12.9.2 Pfizer Business Overview
12.9.3 Pfizer Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.9.4 Pfizer Novel Drug Delivery Systems Product Portfolio
12.9.5 Pfizer Recent Developments
12.10 Takeda
12.10.1 Takeda Company Information
12.10.2 Takeda Business Overview
12.10.3 Takeda Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.10.4 Takeda Novel Drug Delivery Systems Product Portfolio
12.10.5 Takeda Recent Developments
12.11 Bausch&Lomb
12.11.1 Bausch&Lomb Company Information
12.11.2 Bausch&Lomb Business Overview
12.11.3 Bausch&Lomb Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.11.4 Bausch&Lomb Novel Drug Delivery Systems Product Portfolio
12.11.5 Bausch&Lomb Recent Developments
12.12 Samyang Biopharmaceuticals
12.12.1 Samyang Biopharmaceuticals Company Information
12.12.2 Samyang Biopharmaceuticals Business Overview
12.12.3 Samyang Biopharmaceuticals Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.12.4 Samyang Biopharmaceuticals Novel Drug Delivery Systems Product Portfolio
12.12.5 Samyang Biopharmaceuticals Recent Developments
12.13 Johnson & Johnson
12.13.1 Johnson & Johnson Company Information
12.13.2 Johnson & Johnson Business Overview
12.13.3 Johnson & Johnson Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.13.4 Johnson & Johnson Novel Drug Delivery Systems Product Portfolio
12.13.5 Johnson & Johnson Recent Developments
12.14 TOLMAR
12.14.1 TOLMAR Company Information
12.14.2 TOLMAR Business Overview
12.14.3 TOLMAR Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.14.4 TOLMAR Novel Drug Delivery Systems Product Portfolio
12.14.5 TOLMAR Recent Developments
12.15 Astellas
12.15.1 Astellas Company Information
12.15.2 Astellas Business Overview
12.15.3 Astellas Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.15.4 Astellas Novel Drug Delivery Systems Product Portfolio
12.15.5 Astellas Recent Developments
12.16 AMAG Pharmaceuticals
12.16.1 AMAG Pharmaceuticals Company Information
12.16.2 AMAG Pharmaceuticals Business Overview
12.16.3 AMAG Pharmaceuticals Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.16.4 AMAG Pharmaceuticals Novel Drug Delivery Systems Product Portfolio
12.16.5 AMAG Pharmaceuticals Recent Developments
12.17 AbbVie
12.17.1 AbbVie Company Information
12.17.2 AbbVie Business Overview
12.17.3 AbbVie Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.17.4 AbbVie Novel Drug Delivery Systems Product Portfolio
12.17.5 AbbVie Recent Developments
12.18 Dr Reddy
12.18.1 Dr Reddy Company Information
12.18.2 Dr Reddy Business Overview
12.18.3 Dr Reddy Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.18.4 Dr Reddy Novel Drug Delivery Systems Product Portfolio
12.18.5 Dr Reddy Recent Developments
12.19 AstraZeneca
12.19.1 AstraZeneca Company Information
12.19.2 AstraZeneca Business Overview
12.19.3 AstraZeneca Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.19.4 AstraZeneca Novel Drug Delivery Systems Product Portfolio
12.19.5 AstraZeneca Recent Developments
12.20 Aspen
12.20.1 Aspen Company Information
12.20.2 Aspen Business Overview
12.20.3 Aspen Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.20.4 Aspen Novel Drug Delivery Systems Product Portfolio
12.20.5 Aspen Recent Developments
12.21 Acrotech Biopharma
12.21.1 Acrotech Biopharma Company Information
12.21.2 Acrotech Biopharma Business Overview
12.21.3 Acrotech Biopharma Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.21.4 Acrotech Biopharma Novel Drug Delivery Systems Product Portfolio
12.21.5 Acrotech Biopharma Recent Developments
12.22 TWi Pharmaceuticals
12.22.1 TWi Pharmaceuticals Company Information
12.22.2 TWi Pharmaceuticals Business Overview
12.22.3 TWi Pharmaceuticals Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.22.4 TWi Pharmaceuticals Novel Drug Delivery Systems Product Portfolio
12.22.5 TWi Pharmaceuticals Recent Developments
13 REPORT CONCLUSION
14 DISCLAIMER
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Novel Drug Delivery Systems by Type
2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
2.2.2 Liposomes
2.2.3 PEGylated Proteins & Polypeptides
2.2.4 Polymer Nanoparticle
2.2.5 Protein–drug Conjugates
2.2.6 Others
2.3 Novel Drug Delivery Systems by Application
2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
2.3.2 Hospitals & Clinic
2.3.3 Cancer Treatment Centers
2.3.4 Others
2.4 Assumptions and Limitations
3 NOVEL DRUG DELIVERY SYSTEMS BREAKDOWN DATA BY TYPE
3.1 Global Novel Drug Delivery Systems Historic Market Size by Type (2019-2024)
3.2 Global Novel Drug Delivery Systems Forecasted Market Size by Type (2025-2030)
4 NOVEL DRUG DELIVERY SYSTEMS BREAKDOWN DATA BY APPLICATION
4.1 Global Novel Drug Delivery Systems Historic Market Size by Application (2019-2024)
4.2 Global Novel Drug Delivery Systems Forecasted Market Size by Application (2019-2024)
5 GLOBAL GROWTH TRENDS
5.1 Global Novel Drug Delivery Systems Market Perspective (2019-2030)
5.2 Global Novel Drug Delivery Systems Growth Trends by Region
5.2.1 Global Novel Drug Delivery Systems Market Size by Region: 2019 VS 2023 VS 2030
5.2.2 Novel Drug Delivery Systems Historic Market Size by Region (2019-2024)
5.2.3 Novel Drug Delivery Systems Forecasted Market Size by Region (2025-2030)
5.3 Novel Drug Delivery Systems Market Dynamics
5.3.1 Novel Drug Delivery Systems Industry Trends
5.3.2 Novel Drug Delivery Systems Market Drivers
5.3.3 Novel Drug Delivery Systems Market Challenges
5.3.4 Novel Drug Delivery Systems Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Novel Drug Delivery Systems Players by Revenue
6.1.1 Global Top Novel Drug Delivery Systems Players by Revenue (2019-2024)
6.1.2 Global Novel Drug Delivery Systems Revenue Market Share by Players (2019-2024)
6.2 Global Novel Drug Delivery Systems Industry Players Ranking, 2022 VS 2023 VS 2024
6.3 Global Key Players of Novel Drug Delivery Systems Head office and Area Served
6.4 Global Novel Drug Delivery Systems Players, Product Type & Application
6.5 Global Novel Drug Delivery Systems Players, Date of Enter into This Industry
6.6 Global Novel Drug Delivery Systems Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Novel Drug Delivery Systems Market Size (2019-2030)
7.2 North America Novel Drug Delivery Systems Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 North America Novel Drug Delivery Systems Market Size by Country (2019-2024)
7.4 North America Novel Drug Delivery Systems Market Size by Country (2025-2030)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Novel Drug Delivery Systems Market Size (2019-2030)
8.2 Europe Novel Drug Delivery Systems Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Europe Novel Drug Delivery Systems Market Size by Country (2019-2024)
8.4 Europe Novel Drug Delivery Systems Market Size by Country (2025-2030)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Russia
8.10 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Novel Drug Delivery Systems Market Size (2019-2030)
9.2 Asia-Pacific Novel Drug Delivery Systems Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Asia-Pacific Novel Drug Delivery Systems Market Size by Country (2019-2024)
9.4 Asia-Pacific Novel Drug Delivery Systems Market Size by Country (2025-2030)
9.5 China
9.6 Japan
9.7 South Korea
9.8 Southeast Asia
9.9 India
9.10 Australia
10 LATIN AMERICA
10.1 Latin America Novel Drug Delivery Systems Market Size (2019-2030)
10.2 Latin America Novel Drug Delivery Systems Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Latin America Novel Drug Delivery Systems Market Size by Country (2019-2024)
10.4 Latin America Novel Drug Delivery Systems Market Size by Country (2025-2030)
10.5 Mexico
10.6 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Novel Drug Delivery Systems Market Size (2019-2030)
11.2 Middle East & Africa Novel Drug Delivery Systems Market Growth Rate by Country: 2019 VS 2023 VS 2030
11.3 Middle East & Africa Novel Drug Delivery Systems Market Size by Country (2019-2024)
11.4 Middle East & Africa Novel Drug Delivery Systems Market Size by Country (2025-2030)
11.5 Turkey
11.6 Saudi Arabia
11.7 UAE
12 PLAYERS PROFILED
12.1 Amgen
12.1.1 Amgen Company Information
12.1.2 Amgen Business Overview
12.1.3 Amgen Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.1.4 Amgen Novel Drug Delivery Systems Product Portfolio
12.1.5 Amgen Recent Developments
12.2 Teva
12.2.1 Teva Company Information
12.2.2 Teva Business Overview
12.2.3 Teva Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.2.4 Teva Novel Drug Delivery Systems Product Portfolio
12.2.5 Teva Recent Developments
12.3 Roche
12.3.1 Roche Company Information
12.3.2 Roche Business Overview
12.3.3 Roche Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.3.4 Roche Novel Drug Delivery Systems Product Portfolio
12.3.5 Roche Recent Developments
12.4 UCB (Union Chimique Belge)
12.4.1 UCB (Union Chimique Belge) Company Information
12.4.2 UCB (Union Chimique Belge) Business Overview
12.4.3 UCB (Union Chimique Belge) Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.4.4 UCB (Union Chimique Belge) Novel Drug Delivery Systems Product Portfolio
12.4.5 UCB (Union Chimique Belge) Recent Developments
12.5 Celgene
12.5.1 Celgene Company Information
12.5.2 Celgene Business Overview
12.5.3 Celgene Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.5.4 Celgene Novel Drug Delivery Systems Product Portfolio
12.5.5 Celgene Recent Developments
12.6 Merck
12.6.1 Merck Company Information
12.6.2 Merck Business Overview
12.6.3 Merck Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.6.4 Merck Novel Drug Delivery Systems Product Portfolio
12.6.5 Merck Recent Developments
12.7 Gilead Sciences
12.7.1 Gilead Sciences Company Information
12.7.2 Gilead Sciences Business Overview
12.7.3 Gilead Sciences Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.7.4 Gilead Sciences Novel Drug Delivery Systems Product Portfolio
12.7.5 Gilead Sciences Recent Developments
12.8 Sanofi
12.8.1 Sanofi Company Information
12.8.2 Sanofi Business Overview
12.8.3 Sanofi Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.8.4 Sanofi Novel Drug Delivery Systems Product Portfolio
12.8.5 Sanofi Recent Developments
12.9 Pfizer
12.9.1 Pfizer Company Information
12.9.2 Pfizer Business Overview
12.9.3 Pfizer Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.9.4 Pfizer Novel Drug Delivery Systems Product Portfolio
12.9.5 Pfizer Recent Developments
12.10 Takeda
12.10.1 Takeda Company Information
12.10.2 Takeda Business Overview
12.10.3 Takeda Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.10.4 Takeda Novel Drug Delivery Systems Product Portfolio
12.10.5 Takeda Recent Developments
12.11 Bausch&Lomb
12.11.1 Bausch&Lomb Company Information
12.11.2 Bausch&Lomb Business Overview
12.11.3 Bausch&Lomb Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.11.4 Bausch&Lomb Novel Drug Delivery Systems Product Portfolio
12.11.5 Bausch&Lomb Recent Developments
12.12 Samyang Biopharmaceuticals
12.12.1 Samyang Biopharmaceuticals Company Information
12.12.2 Samyang Biopharmaceuticals Business Overview
12.12.3 Samyang Biopharmaceuticals Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.12.4 Samyang Biopharmaceuticals Novel Drug Delivery Systems Product Portfolio
12.12.5 Samyang Biopharmaceuticals Recent Developments
12.13 Johnson & Johnson
12.13.1 Johnson & Johnson Company Information
12.13.2 Johnson & Johnson Business Overview
12.13.3 Johnson & Johnson Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.13.4 Johnson & Johnson Novel Drug Delivery Systems Product Portfolio
12.13.5 Johnson & Johnson Recent Developments
12.14 TOLMAR
12.14.1 TOLMAR Company Information
12.14.2 TOLMAR Business Overview
12.14.3 TOLMAR Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.14.4 TOLMAR Novel Drug Delivery Systems Product Portfolio
12.14.5 TOLMAR Recent Developments
12.15 Astellas
12.15.1 Astellas Company Information
12.15.2 Astellas Business Overview
12.15.3 Astellas Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.15.4 Astellas Novel Drug Delivery Systems Product Portfolio
12.15.5 Astellas Recent Developments
12.16 AMAG Pharmaceuticals
12.16.1 AMAG Pharmaceuticals Company Information
12.16.2 AMAG Pharmaceuticals Business Overview
12.16.3 AMAG Pharmaceuticals Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.16.4 AMAG Pharmaceuticals Novel Drug Delivery Systems Product Portfolio
12.16.5 AMAG Pharmaceuticals Recent Developments
12.17 AbbVie
12.17.1 AbbVie Company Information
12.17.2 AbbVie Business Overview
12.17.3 AbbVie Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.17.4 AbbVie Novel Drug Delivery Systems Product Portfolio
12.17.5 AbbVie Recent Developments
12.18 Dr Reddy
12.18.1 Dr Reddy Company Information
12.18.2 Dr Reddy Business Overview
12.18.3 Dr Reddy Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.18.4 Dr Reddy Novel Drug Delivery Systems Product Portfolio
12.18.5 Dr Reddy Recent Developments
12.19 AstraZeneca
12.19.1 AstraZeneca Company Information
12.19.2 AstraZeneca Business Overview
12.19.3 AstraZeneca Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.19.4 AstraZeneca Novel Drug Delivery Systems Product Portfolio
12.19.5 AstraZeneca Recent Developments
12.20 Aspen
12.20.1 Aspen Company Information
12.20.2 Aspen Business Overview
12.20.3 Aspen Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.20.4 Aspen Novel Drug Delivery Systems Product Portfolio
12.20.5 Aspen Recent Developments
12.21 Acrotech Biopharma
12.21.1 Acrotech Biopharma Company Information
12.21.2 Acrotech Biopharma Business Overview
12.21.3 Acrotech Biopharma Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.21.4 Acrotech Biopharma Novel Drug Delivery Systems Product Portfolio
12.21.5 Acrotech Biopharma Recent Developments
12.22 TWi Pharmaceuticals
12.22.1 TWi Pharmaceuticals Company Information
12.22.2 TWi Pharmaceuticals Business Overview
12.22.3 TWi Pharmaceuticals Revenue in Novel Drug Delivery Systems Business (2019-2024)
12.22.4 TWi Pharmaceuticals Novel Drug Delivery Systems Product Portfolio
12.22.5 TWi Pharmaceuticals Recent Developments
13 REPORT CONCLUSION
14 DISCLAIMER
